Should I buy or sell Prenetics Global stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRE shares. View PRE analyst ratings or view top-rated stocks .

What is Prenetics Global's stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Prenetics Global's stock. Their PRE share price targets range from $9.00 to $9.00. On average, they predict the company's share price to reach $9.00 in the next year. This suggests a possible upside of 210.3% from the stock's current price. View analysts price targets for PRE or view top-rated stocks among Wall Street analysts .

How have PRE shares performed in 2024?

Prenetics Global's stock was trading at $5.91 at the start of the year. Since then, PRE stock has decreased by 50.9% and is now trading at $2.90. View the best growth stocks for 2024 here .

Are investors shorting Prenetics Global?

Prenetics Global saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,800 shares, an increase of 60.0% from the March 15th total of 8,000 shares. Based on an average daily trading volume, of 69,600 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are short sold. View Prenetics Global's Short Interest .

When is Prenetics Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024. View our PRE earnings forecast .

How were Prenetics Global's earnings last quarter?

Prenetics Global Limited (NASDAQ:PRE) released its earnings results on Friday, September, 15th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.15. The firm had revenue of $5.70 million for the quarter. Prenetics Global had a negative trailing twelve-month return on equity of 11.15% and a negative net margin of 193.60%.

When did Prenetics Global's stock split?

Shares of Prenetics Global reverse split on Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Prenetics Global?

Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRE

Prenetics Global (PRE) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free PRE Stock Alerts

$2.90

-0.29 (-9.09%)

(As of 05:21 PM ET)

Compare

Today's Range: $2.85
▼
$3.22
50-Day Range: $3.15
▼
$5.67
52-Week Range: $2.85
▼
$15.90

Volume: 39,526 shs
Average Volume: 70,194 shs
Market Capitalization: $26.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Prenetics Global alerts:

Prenetics Global MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 210.3% Upside
$9.00 Price Target
Short Interest: Healthy
0.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

772nd out of 911 stocks

Holding & Other Investment Offices Industry

8th out of 10 stocks

3.5

Analyst's Opinion

Consensus Rating
Prenetics Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Prenetics Global has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.17% of the float of Prenetics Global has been sold short.
Short Interest Ratio / Days to Cover
Prenetics Global has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Prenetics Global has recently increased by 60.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Prenetics Global does not currently pay a dividend.
Dividend Growth
Prenetics Global does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRE.

0.6

News and Social Media Coverage

Search Interest
6 people have searched for PRE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prenetics Global insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Prenetics Global is held by insiders.
Percentage Held by Institutions
Only 25.01% of the stock of Prenetics Global is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Prenetics Global is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prenetics Global is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prenetics Global has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Prenetics Global Stock (NASDAQ:PRE)

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

PRE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRE Stock News Headlines

April 6, 2024 | benzinga.com

Prenetics Global Stock (NASDAQ:PRE), Analyst Ratings, Price Targets, Predictions

April 3, 2024 | baystreet.ca

Prenetics Flat on Financial Results

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 1, 2024 | finanznachrichten.de

Prenetics Global Limited: Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results

April 1, 2024 | benzinga.com

Prenetics Global: Q4 Earnings Insights

April 1, 2024 | investorplace.com

PRE Stock Earnings: Prenetics Global Beats EPS, Misses Revenue for Q4 2023

April 1, 2024 | globenewswire.com

Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results

February 9, 2024 | finance.yahoo.com

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

February 9, 2024 | globenewswire.com

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

January 17, 2024 | msn.com

Prenetics Global files to sell 1.48M Class A shares for holders

December 18, 2023 | investing.com

Prenetics Global (PRE) Earnings Dates & Reports

December 17, 2023 | seekingalpha.com

PRENW Prenetics Global Limited WT EXP 051827

November 20, 2023 | benzinga.com

Prenetics Global Stock (NASDAQ:PRE) Insider Trades

November 20, 2023 | msn.com

Prenetics Global GAAP EPS of -$0.08, revenue of $4.86M

November 20, 2023 | benzinga.com

Prenetics Global: Q3 Earnings Insights

November 20, 2023 | finance.yahoo.com

Prenetics Announces Third Quarter 2023 Financial Results

November 11, 2023 | finance.yahoo.com

Prenetics Global Limited (NASDAQ:PRE): Is Breakeven Near?

November 5, 2023 | morningstar.com

Prenetics Global Ltd Class A PRE

November 1, 2023 | msn.com

Prenetics Global announces reverse stock split

November 1, 2023 | finance.yahoo.com

Prenetics Global Limited Announces Reverse Stock Split

October 30, 2023 | money.usnews.com

Prenetics Global Limited - Ordinary Shares - Class A

October 3, 2023 | finance.yahoo.com

Genetic Genealogy Market | Direct-To-Customer Segment Registered The Highest Growth - Here's Why

September 15, 2023 | finanznachrichten.de

Prenetics Global Limited: Prenetics Announces Second Quarter 2023 Financial Results

September 15, 2023 | finance.yahoo.com

Prenetics Announces Second Quarter 2023 Financial Results

September 10, 2023 | finance.yahoo.com

PRE - Prenetics Global Limited

August 29, 2023 | finance.yahoo.com

A World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on Television

See More Headlines

Receive PRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/15/2023
Today: 4/19/2024
Next Earnings (Estimated): 6/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Holding & other investment offices
Sub-Industry: N/A
Current Symbol: NASDAQ:PRE
CUSIP: N/A
CIK: 1876431
Web: www.prenetics.com
Phone: 852-2210-9588
Fax: N/A
Employees: 400
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $9.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +187.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.7985)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,720,000.00
Net Margins: -193.60%
Pretax Margin: -260.63%
Return on Equity: -11.15%
Return on Assets: -9.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.37
Quick Ratio: 2.29

Sales & Book Value

Annual Sales: $21.74 million
Price / Sales: 1.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $23.00 per share
Price / Book: 0.14

Miscellaneous

Outstanding Shares: 9,140,000
Free Float: 8,424,000
Market Cap: $28.61 million
Optionable: Not Optionable
Beta: -0.11

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Sheng Wu Yeung (Age 45)
Co-Founder & CEO
Dr. Chi Hung Tzang Ph.D. (Age 49)
Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board
Mr. Hoi Chun Lo (Age 39)
Chief Financial Officer
Dr. Yung Ho Wong DPHIL (Age 42)
Chief Technology Officer
Ms. Yvonne L. Wong
Chief Corporate Development Officer
Ms. Samantha Kwok
Vice President People & Culture
Dr. Senthil Sundaram M.D. (Age 50)
Chief Clinical Officer
Mr. Avrom Boris Lasarow (Age 47)
Chief Executive Officer of EMEA
Dr. Shih-Chang Ong M.D. (Age 46)
Chief Medical Officer & Member of Scientific Advisory Board
Mr. Joel Neoh
Chief Consumer Officer & MD for CircleDNA

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Prenetics Global stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRE shares.
View PRE analyst ratings or view top-rated stocks.
What is Prenetics Global's stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for Prenetics Global's stock. Their PRE share price targets range from $9.00 to $9.00. On average, they predict the company's share price to reach $9.00 in the next year. This suggests a possible upside of 210.3% from the stock's current price.
View analysts price targets for PRE or view top-rated stocks among Wall Street analysts.
How have PRE shares performed in 2024?: Prenetics Global's stock was trading at $5.91 at the start of the year. Since then, PRE stock has decreased by 50.9% and is now trading at $2.90.
View the best growth stocks for 2024 here.
Are investors shorting Prenetics Global?: Prenetics Global saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,800 shares, an increase of 60.0% from the March 15th total of 8,000 shares. Based on an average daily trading volume, of 69,600 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are short sold.
View Prenetics Global's Short Interest.

When is Prenetics Global's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024.
View our PRE earnings forecast.
How were Prenetics Global's earnings last quarter?: Prenetics Global Limited (NASDAQ:PRE) released its earnings results on Friday, September, 15th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.15. The firm had revenue of $5.70 million for the quarter. Prenetics Global had a negative trailing twelve-month return on equity of 11.15% and a negative net margin of 193.60%.
When did Prenetics Global's stock split?: Shares of Prenetics Global reverse split on Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
How do I buy shares of Prenetics Global?: Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial